Overview

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.

Phase:

Phase 4

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone
Xhance